AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) has received an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports.

Brokers have set a 1-year consensus price objective of $5.50 for the company and are expecting that the company will post $0.04 earnings per share for the current quarter, according to Zacks. Zacks has also assigned AEterna Zentaris an industry rank of 64 out of 255 based on the ratings given to related companies.

Several research analysts have recently weighed in on AEZS shares. ValuEngine raised shares of AEterna Zentaris from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. HC Wainwright reissued a “buy” rating on shares of AEterna Zentaris in a report on Thursday, January 17th. Finally, Zacks Investment Research cut shares of AEterna Zentaris from a “buy” rating to a “hold” rating in a report on Friday, March 15th.

Shares of AEZS traded up $0.05 during mid-day trading on Tuesday, hitting $4.02. 297,733 shares of the company traded hands, compared to its average volume of 335,917. AEterna Zentaris has a 1 year low of $1.29 and a 1 year high of $5.57. The stock has a market capitalization of $64.94 million, a price-to-earnings ratio of 15.76 and a beta of 1.25.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last released its quarterly earnings data on Tuesday, March 26th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.12). AEterna Zentaris had a net margin of 15.67% and a return on equity of 55.49%. The company had revenue of $1.40 million for the quarter, compared to analysts’ expectations of $0.25 million. On average, equities analysts predict that AEterna Zentaris will post 2.25 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in the business. Virtu Financial LLC bought a new position in shares of AEterna Zentaris in the third quarter worth approximately $101,000. Acadian Asset Management LLC boosted its position in shares of AEterna Zentaris by 27.2% in the fourth quarter. Acadian Asset Management LLC now owns 45,049 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 9,640 shares during the period. O Shaughnessy Asset Management LLC bought a new position in shares of AEterna Zentaris in the fourth quarter worth approximately $66,000. Finally, Jane Street Group LLC bought a new position in shares of AEterna Zentaris in the fourth quarter worth approximately $30,000. 15.29% of the stock is owned by institutional investors and hedge funds.

About AEterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.

Featured Story: Return on Equity (ROE)

Get a free copy of the Zacks research report on AEterna Zentaris (AEZS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.